Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SOD1 | P00441 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15295402 | 0.88 | ALDH1A1 (0.65) | KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL9610288 | 0.87 | NPSR1 (0.43) | KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL74478 | 0.86 | NPSR1 (0.54) | KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL10224057 | 0.85 | TAAR1 (0.46) | KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL10223981 | 0.83 | GGPS1 (0.42) | KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL8057463 | 0.82 | ALDH1A1 (0.59) | KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL18067905 | 0.81 | MAPK1 (0.62) | KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL10799020 | 0.81 | KDM4E (0.58) | KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL4487459 | 0.81 | KDM4E (0.68) | KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL59488 | 0.80 | KDM4E (0.61) | KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242504-A1 | DEUTERIUM-ENRICHED PIPERIDINONYL-OXOISOINDOLINYL ACETAMIDES AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | DEUTERX LLC (US) | 2023-08-03 | — | — | US | disclosed |
| US-11535603-B1 | Deuterium-enriched piperidinonyl-oxoisoindolinyl acetamides and methods of treating medical disorders using same | DEUTERX, LLC (US) | 2022-12-27 | — | — | US | disclosed |
| US-8148367-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100105665-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
| WO-2008089005-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105665-A1 | RENIN INHIBITORS | REN, ACE, AGT | KDM4E 2733/4885ALDH1A1 947/4885SMN1; SMN2 4547/4885 |
| US-20230242504-A1 | DEUTERIUM-ENRICHED PIPERIDINONYL-OXOISOINDOLINYL ACETAMIDES AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | EGLN3, HPGDS, EGLN2 | KDM4E 1112/4885ALDH1A1 2487/4885SMN1; SMN2 2161/4885 |
| US-11535603-B1 | Deuterium-enriched piperidinonyl-oxoisoindolinyl acetamides and methods of treating medical disorders using same | EGLN3, HPGDS, EGLN2 | KDM4E 1112/4885ALDH1A1 2487/4885SMN1; SMN2 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.